Physician profile
Michael Zhang
NPI 1710336508
$1,445.22
in general payments reported to CMS, 2019-2025
22 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.05 · 2020: $70.95 · 2021: $51.93 · 2022: $80.33 · 2023: $371 · 2024: $469 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $247.93 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $161.98 | 2023-2025 | Lifevest |
| Abbvie INC. | $145.50 | 2021-2025 | Ubrelvy, Qulipta, Dalvance |
| Pfizer INC. | $126.68 | 2020-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.74 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $102.58 | 2023-2024 | Aptiom |
| Alnylam Pharmaceuticals INC. | $82.37 | 2023-2025 | Onpattro, Givlaari |
| Biohaven Pharmaceutical Holding Company LTD. | $80.33 | 2022 | |
| Gilead Sciences, INC. | $53.96 | 2019 | |
| Neurelis, INC. | $48.84 | 2023 | Valtoco |
| Ucb, INC. | $44.97 | 2023-2024 | Fintepla |
| Mdd US Operations, LLC | $39.16 | 2023 | Gocovri |
| Octapharma USA, INC. | $32.56 | 2024 | Panzyga |
| Alexion Pharmaceuticals, INC. | $21.70 | 2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $20.33 | 2023 | Ponvory |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20.15 | 2020 | |
| Neurocrine Biosciences, INC. | $17.25 | 2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $16.09 | 2019 | |
| Melinta Therapeutics, LLC | $15.47 | 2020 | |
| Janssen Biotech, INC. | $15.12 | 2025 | |
| Amneal Pharmaceuticals LLC | $14.52 | 2024 | Rytary |
| Allergan, INC. | $12.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.